Results 51 to 60 of about 289,934 (317)
Molecular Oncology, EarlyView.BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi +11 more
wiley +1 more source
Taiwanese Journal of Obstetrics & Gynecology, 2005 Objective: Retroverted impacted adenomyosis may cause progressive lower urinary bladder compression, resulting in bladder outflow obstruction and lower urinary tract symptoms.
Pu-Tsui Wang, Jenn-Ming Yang
doaj +1 more source
Technology in Cancer Research & Treatment, 2020 Objective: We aimed to explore the diagnostic value of microRNA-192 expression in urinary sediment combined with B-ultrasound in the diagnosis of bladder cancer.
Fuquan Jiang PhD +3 more
doaj +1 more source
Mullerianosis of the Urinary Bladder
Indian Journal of Urology, 2012 Mullerianosis of the urinary bladder is a rare and morphologically complex tumor-like lesion, composed of several types of mullerian lesions like endometriosis, endocervicosis, and endosalpingiosis. This disease occurs in women of reproductive age group. Implantative and metaplastic origins have been suggested in the pathogenesis.
Ranjini Kudva, Padmaraj Hegde
openaire +3 more sources
FEBS Open Bio, EarlyView.Bisphenol A (BPA), a common chemical in plastics, exerts dual effects on bladder cancer cells: low doses promote growth and migration, while high doses suppress growth and migration. Multi‐omics and bioinformatics reveal BPA acts via MAPK and inflammatory pathways.
Shaomin Niu +10 more
wiley +1 more source
Botulinum toxin-A for the treatment of overactive bladder: UK contributions
, 2013 Background: Botulinum toxin-A (BoNT/A) is now established second-line management for refractory overactivebladder (OAB) and recognised in many incontinence guidelines and pathways.
Fowler, CJ +13 more
core +1 more source
Non-muscle-invasive clear cell carcinoma of the urinary bladder: Is cystectomy necessary? [PDF]
, 2019 We report the clinical presentation, histological findings and management of a 49-year-old female patient with non-muscle-invasive clear cell carcinoma of the urinary bladder. In the literature, there are only seven such case reports.
Sanjeev Madaan +3 more
core +1 more source
Bladder catheterization as a risk factor for urinary tract infection
, 2022 Introduction: Bladder catheterization contributes significantly to the occurrence of urinary tract infections. This is a common problem in health care both in Poland and around the world.
Sylwia Kocur +7 more
core +1 more source
Derivation and characterization of retinal pigment epithelium from urine‐derived iPSCs
FEBS Open Bio, EarlyView.Age‐related macular degeneration causes vision loss via RPE dysfunction and loss. Traditional iPSC therapies rely on invasive biopsies, limiting scalability. Here, we utilize urine‐derived stem cells as an accessible source to generate u‐iPSCs, successfully differentiated into pigmented RPE. This “Urine‐to‐Retina” platform provides a promising path for
Daniella Beiner +7 more
wiley +1 more source
A case of signet ring cell adenocarcinoma of the bladder with spontaneous urinary extravasation
Indian Journal of Urology, 2011 Primary signet ring cell adenocarcinoma (PSRCC) of the bladder is a relatively rare variant of adenocarcinoma of the bladder with poor prognosis. Also PSRCC of the bladder presenting with spontaneous urinary extravasation is very rare.
Sanish S Shringarpure +3 more
doaj +1 more source